Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.10 0.07% 148.10 148.40 148.60 152.00 146.00 152.00 531,449 16:35:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 473.2 -126.5 -14.6 - 1,087

Indivior Share Discussion Threads

Showing 3676 to 3697 of 3750 messages
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
wondering what next resistence level might be
Hardly. Just levelling out before the next push. Its getting ready to move up.
Dropping back
Back over 400p we go. Been a long time coming. An absolute gem of an RNS last night.
Real-time Estimate Quote. Real-time Estimate CHI-X - 01/26 03:31:25 am 144.45 GBX +12.94% Looking good Billyray
Yes,couldn't agree more,a period without a litigation debacle coming out of the mist would be most welcome.I sold out when the RCOL legal filing emerged and then felt obliged to buy back in at a higher price a couple of weeks back!Think I'll just confine the current holding to long term locker ....he says hopefully.
well the after hours RNS at least removes the Reckitt indemnity uncertainty. Itcould have hung around and depressed the share price for years. The $50m settlement payable over five years is a result just to put it behind u. How about a decent run with fewer banana skins. They can get tiresome!
Definitely a good day today, moving up nicely!
Iain Gilbert Sharecast News 19 Jan, 2021 16:46 19 Jan, 2021 16:46 , Indivior Jefferies included drugs manufacturer Indivior on their latest quarterly list of 15 key buy ideas in the UK small and mid-cap space. Analyst Harry Sephton argued that the company's shares were not pricing in "sufficient upside" for Sublocade, the company's treatment for medium-to-severe opioid addiction. He estimated financial markets were pricing in peak sales below $250.0m for Sublocade, projections that he believed were "too conservative". To back up his case, Sephton pointed out how sales of Sublocade were already running at an annual pace of approximately $150.0m and continuing to grow "incrementally". Furthermore, the patient population was growing at a double-digit pace and proprietary surveys showed that doctors were anticipating a significant uptake over the next five years. Covid-19 restrictions had also been hampering sales and marketing activity for Sublocade, but that was expected to change. Sephton had a 'buy' recommendation and 180.0p target price on Indivior's shares, using a sum-of-the-parts net present valuation method and a 10% weighted average cost of capital to derive the latter.
RE: Interesting analysis of Indivior (Litigation Investor)Today 14:44 This Report is excellent, very comprehensive & well worth the read. Some of the points it makes are as follows: "Suboxone sales have remained resilient in the face of generic competition (and even saw modest growth in the most recent quarter, Q3 2020) Sublocade unit growth is accelerating (growing 15% in Q3 2020 over Q2 2020) Sublocade sales should easily exceed management guidance A competitive entrant, Brixadi, has been delayed (likely, >12 months) as Braeburn (Brixadi's license holder in the U.S.) received a complete response letter from the FDA. Based on our projections for Sublocade sales growth it is easy to see a near term value for Indivior ordinary shares of 200p." It also states that the Reckitt claim is a " baseless preliminary claim filed by Indivior’s former parent company" that is "procedurally defective and substantively precluded due to Reckitt’s alleged acts of fraud or dishonesty." I agree with the Report and believe that the Reckitt claim was a crude attempt to try & stifle a much stronger claim by INDV on Reckitt. This is also the view taken by the Report. It goes on to forecast an share price of £5 for INDV by 2025 based on INDV's market leading position and on the growth of SUBLOCADE as well as other products supplied by INDV using their monthly injectable technology such as PERSERIS designed to combat Schizophrenia. INDV's share price should continue to firm from here on the run-up to releasing its full year results on 18th February.
Conclusion We believe the overhang on Indivior's stock due to Reckitt's "reckless" claim will soon be lifted as the claim is either resolved or never actually instituted. At that time, the market can finally focus on the tremendous growth potential of Indivior's life saving medications. We believe the company's stock represents a strong buy at current levels and would recommend buying shares in anticipation of such positive catalysts. FROM SEEKING ALPHA
Indivior is the biggest FTSE 250 gainer today. Would I buy it now? Manika Premsingh | Friday, 15th January, 2021 Business development to success and FTSE 100 250 350 growth concept. The FTSE 250 opioid addiction treatment provider Indivior (LSE: INDV) is the biggest index gainer today as I write. Its share price is up 9%, continuing its recovery after a sharp fall in late November. Why the share price rose INDV’s better-than-expected financial results are the clear reason for the uptick in share price. It now expects revenue to be at least $25m higher than it had expected earlier for the full year. It also expects expenses to be lower, resulting in an improved income forecast. What’s next for the INDV share price I reckon that the latest news will provide continued impetus for INDV’s share price. It’s now at 115p, up from the sub-100p levels it was at before the last week of December. The big decline started in late November, when it crashed 30% in a day following news that its former parent company — Reckitt Benckiser — had filed a £1bn claim on it. Even now the share price is still much lower than its 131p levels at the time. But at least it’s now closer than ever to getting back there. When I last wrote about Indivior, after its share price fall, my sense was that its share price would be dependent more on its own performance than anything else. If the share price reaction to its latest results is anything to go by, it only proves the point I was making at the time. If its performance remains consistent, I reckon that its share price can climb up further. This is especially so in today’s bullish market, where investors are rewarding companies that are performing well. Battling the opioid crisis Moreover, the seriousness of the opioid crisis is big and rising, an issue that Indivior is well placed to address. According to the World Health Organisation, globally 0.5m deaths are caused by drug use every year, of which 70% are opioid-related. Moreover, between 2010 and 2018, the number of people dying of opioid overdose in the US increased by 120%. Past problems still haunt Despite this, as an investor I’m cautious because of INDV’s problems from the recent past, which include accusations of mis-selling and resulted in its former CEO being imprisoned. Almost two months after I wrote about INDV, it indeed appears to have put the episode behind it. It has also said that Reckitt Benckiser’s claim is without merit. Further, its financials had suffered quite the blow in the first nine months of 2020, with a sharp decline in revenue. The latest numbers, then, are a surprise development and not one that reflects the inherent, ongoing strength of the company. I think the INDV stock looks much better after its results than it did two months ago when it was far more in the thick of a crisis. It could continue to see improvements from here. But I really want to see some more predictability to its financials before buying the stock. Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned.
grupo guitarlumber
They have a 320 tp and their view is no risk on the indemnity claim.My own view is that will still weigh on the price whilst its there and prob 200-250p is close to fv now
Https:// Https:// baddeal 15 Jan '21 - 10:06 - 3115 of 3115 0 0 0 Numis reiterate their sotp valuation at c3gbp. Let’s hope they’re right What share price would that be
Numis reiterate their sotp valuation at c3gbp. Let's hope they're right
RNS Number : 7823L Indivior PLC 15 January 2021 Indivior Provides Preliminary FY 2020 Financial Results Ahead of Guidance This Release Contains Inside Information. Slough, UK, and Richmond, VA, January 15, 2021 - The Group is providing the below preliminary unaudited financial results based on current financial information for the year ended December 31, 2020. -- Total net revenue is now expected to be in the range of $645m to $650m (guidance $595m to $620m) due to: o Expected SUBLOCADE(R) net revenue between $128m to $130m (guidance of $120m to $125m), which represents preliminary Q4 2020 SUBLOCADE(R) net revenue growth of 12% to 18% versus Q3 2020 reported SUBLOCADE(R) net revenue of $33m; o The relative resilience of SUBOXONE(R) Film share through the end of FY 2020 as well as benefits from modest stocking activity in the U.S. in the fourth quarter; and, o Expected PERSERIS(R) net revenue consistent with guidance of $12m to $15m. -- An operating expense base (SG&A and R&D combined) that is expected to be slightly below guidance of $470m to $480m. Based on these preliminary results, the Group now expects to deliver adjusted pre-tax income ahead of its previous expectations. Indivior expects to report FY 2020 results on February 18, 2021.
Good results can see 1.40 coming soon
11 January 2021 Indivior PLC - Directorate Change Indivior PLC announces that Daniel Tassé has notified the Board of his intention to stand down as a Non-Executive Director of the Company in order to focus on his increasing business commitments. Mr Tassé will not stand for re-election at the Company's next Annual General Meeting and will stand down at the conclusion of that meeting. Daniel Tassé has been a Non-Executive Director for over six years and is currently Senior Independent Director, Chair of the Audit Committee and a member of the Remuneration Committee. As announced in November 2020, a search is underway to identify an additional independent Non-Executive Director with recent and relevant financial experience and the search has been expanded to identify a further Non-Executive Director. Graham Hetherington, Chair of the Board of Indivior PLC, commented: 'Daniel joined the Board in 2014 and was appointed Senior Independent Director in 2016. He has been a strong contributor since the Company's listing. His strategic and commercial experience and acumen have been invaluable, as was his strong leadership while stepping in as Interim Chair in June 2020 at a critical time for the Company. On behalf of the entire Board, I would like to extend our thanks to Daniel and wish him well. This announcement is made pursuant to Listing Rule 9.6.11(2).
Price (GBX) 105.10 3.04% (3.10) Open / Last close 104.80 / 105.10 High / Low 106.80 / 102.40 Bid / Offer 104.90 / 105.10 Special Condition: - Trading Status: Market Close FTSE 250 As at 10.01.21 16:35:26 - All data delayed at least 15 minutes
Looking better here today....................??
Upcoming events on INDIVIOR February/18/2021 FY 2020 Earnings Release (Projected)
THE WISH LIST GIVING BOXES,Supports and Resistences to determine channels and trends together with broker targets which might of course make you smile or and smirk 70 to 80p 80 to 90p 90 to 100p 100 to 110p$$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$ 110 to 120p 120 to 130p 130 to 140p 140 to 150p 150 to 160p 160 to 170pCiti target 165p 170 to 180p 180 to 190p 190 to 200p Jefferies target 200p Https:// DECEMBER END 2019 GIVES 39p which puts us into the 30 to 40p BOX again June ends in the 80 to 90p BOX at 83p July ends at 137.60p August ends at 118.70p September ends at 117p October ends at 110.30p November ends at 101.10p December ends at 108.80p Http:// Https:// Upcoming events on INDIVIOR February/18/2021 FY 2020 Earnings Release (Projected) INVVY ADR USD EQUAL TO 5 INDV SHARES Https://
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210517 01:42:40